Syngene International Limited is undergoing a leadership transition as it reshuffles its executive lineup. The company has announced that Caroline Hempstead, currently serving as Interim Chief Commercial Officer, will leave by mutual consent on April 30, 2026. She will be succeeded on May 1, 2026 by Abhijit Zutshi, who has been appointed Chief Commercial Officer and will join Syngene’s Executive Committee. In parallel, the company said Andrew Webster, its Chief Human Resources Officer, will depart by mutual consent on April 30, 2026, and will be replaced from May 1, 2026 by Maninder Singh Puri as Chief Human Resources Officer, also a member of the Executive Committee. Additionally, Dr. Kenneth Barr, Head of SynVent and Strategic Collaborations, will leave the organization by mutual consent effective April 30, 2026.
Background details released with the announcement show that Abhijit Zutshi is currently Biocon Limited’s Chief Commercial Officer, responsible for its Generics business, and will bring a deep commercial track record to Syngene. Maninder Singh Puri, the incoming CHRO, is described as currently serving as Head of Human Resources for Biocon’s Generics Business and Biocon Academy, with experience spanning marketing, sales, business development and HR leadership. Kenneth Barr’s departure marks the end of his tenure leading SynVent and strategic collaborations. The company noted that more information will be available on its website as part of the disclosure.
Together, the moves mark a targeted transition in Syngene’s senior leadership, aligning the commercial and human resources functions with leaders who have operating experience across Biocon and its ecosystem. As these new appointments take effect in early May, Syngene will be watching closely to ensure a smooth handover and continued focus on advancing its growth agenda across its partnered and internal programs.